Donate
Home
About the LRG
Patient Support
LRG Research
LRG Library
Medical Professionals
The Life Raft Group - Ensuring that no one has to face GIST alone The Life Raft Group - Ensuring that no one has to face GIST alone
I'm John. Father of three and grandfather of three. Melinda and I want to make what we do today help everyone with GIST tomorrow.
I'm John. Father of three and grandfather of three. Melinda and I want to make what we do today help everyone with GIST tomorrow.
The Life Raft Group - Ensuring that no one has to face GIST alone
About GIST
Frequent Topics
Accessing Treatment
Coping with Cancer

Rash and Skin Problems

Mild Rashes | Moderate Rashes | Severe Rashes | Nerve Pain | Dry Skin | Helpful Sites

Caution: It is important for patients to report side effects and discuss their management with their doctor. The material presented here is for information purposes only; it is not a substitute for talking to your doctor.


Rashes are a common side effect of Gleevec

 

Gleevec-induced rashes vary from mild to severe. Rashes occur more frequently in females and at higher doses with gender appearing to be the more important factor.

Rash varies in cause and treatment:

  • Shingles (treated with antiviral, steroids makes it worsen)
  • True Gleevec drug rash (most common)
  • Heat sensitivity
  • Fungal infection (ringworm, steroids may make it worsen)
  • Cellulitis (requires an antibiotic)

Rashes may require referral to a dermatologist and are the most common side effect requiring permanent discontinuation of Gleevec.

to top

Mild Rashes

Most cases are mild and self-limiting and are treatable with antihistamines or topical steroids.

Some of the remedies that patients have reported as effective are:

  • Neutrogena anti-itch lotion
  • Florisone
  • Zyrtec
  • Sarna cream
  • Gold Bond medicated anti-itch cream
Watch the LRG Webcast: The Superficial Side of GIST: Taking Care of Your Skin During Therapy
Presenter: Dr. Mario Lacouture
Director of the Cancer Skin Care Program at Northwestern University

Presented: February 24 at 12:00 p.m. EST-Eastern Standard Time
Duration: 59 minutes

The introduction of new drugs such as Gleevec and Sutent, which target specific mechanisms involved in GIST, has resulted in remarkable improvements. Despite this success, a significant number of patients treated with these drugs will develop dermatological side effects, such as hand foot syndrome, dry skin, hair loss, and rashes, which lead to decreased quality of life and inconsistent drug administration. All of which may affect a person's sense of well being and clinical benefit. Therefore, attentive dermatological care is critical for the optimization of GIST therapies and quality of life.

PLAY

Mario Lacouture


Dr. Mario Lacouture
Director of Cancer Skin Program at
Northwestern University

 

Moderate Rashes

Rashes of moderate severity may respond to oral steroids, such as prednisone (depending on the cause).

to top

Severe Rashes1

Depending on cause, severe rashes may require discontinuation of Gleevec and systemic steroids. After the rash resolves, Gleevec is often restarted with prednisone. The prednisone is then tapered off over the course of several weeks.

NOTE: This excerpt on dealing with severe rashes comes from "Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib"
By Michael W. N. Deininger, Stephen G. O’Brien, John M. Ford, and Brian J. Druker.
"In some patients, severe rashes develop with desquamative components, including a report of Stevens-Johnson syndrome. In such cases, immediate discontinuation of therapy and systemic steroids (eg, 1 mg/kg/d) are indicated. Severe skin reactions that were resistant to supportive measures were the most frequent cause for permanent discontinuation of imatinib therapy. However, the incidence of this event is small (1% of all patients). Depending on the clinical situation, it has been possible to restart imatinib after the rash has resolved. In these cases, prednisone has typically been given at 1 mg/kg/d, tapering to 20 mg per day over several weeks. Imatinib has been restarted at 100 mg per day and the dose increased by 100 mg per week while tapering the steroids, assuming that the rash has not recurred. This approach should only be considered in patients for whom no other treatment option exists other than imatinib."

to top

Other Skin-related Problems

Nerve Pain

A few patients have reported a sensation like "pins and needles" on their skin. Talk to your doctor about this type of symptom. They may indicate a type of nerve-related pain/damage. Some patients have reported relief from Neurontin. Note that Neurontin provides pain relief, but does not prevent nerve damage.

to top

Dry Skin

Patients sometimes report very dry skin while taking Gleevec. Often this can be managed the same way that dry skin is normally managed. The Mayo Clinic has a good overview of dry skin causes and management. More severe cases (which are rare) require the help of your doctor or a dermatologist.

Your skin is protected by oils. If you remove the protective oils by bathing too often or using harsh soaps, your skin will be more prone to dry out. Some general suggestions to manage dry skin include:

  • Short showers are better than baths.
  • Use warm, not hot water.
  • Avoid harsh soaps and detergents. Try mild cleansers like Aveeno or Cetaphil or mild soaps like Neutrogena or Dove.
  • Moisturize after a bath when your skin is still damp and as often as needed.
  • Avoid products with alcohol.
  • Thick moisturizers work best.
  • Use a humidifier if the air is dry (in winter); but don't forget to clean it regularly.
  • Drink plenty of water.

 

Thank you to LRG members for providing these tips.

 

to top

 

Helpful Sites

Cutaneous Drug Reactions (Technical information about skin reactions caused by drugs) (Pharmacol Rev. 2001 Sep;53(3):357-79.)

to top

 

 


Return to Side Effects Page

 

References

1. Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib
By Michael W. N. Deininger, Stephen G. O’Brien, John M. Ford, and Brian J. Druker
J Clin Oncol 21. © 2003 by American Society of Clinical Oncology

This website is accredited by Health On the Net Foundation. Click to verify. We subscribe to the HONcode principles. Verify Here
This website is dedicated in perpetuity to the memory of Mary S. Golnik
JT IMAGES, Inc. - Website designer
© Copyright 2009 Life Raft Group. All rights Reserved.
Last Modified - November 22, 2011 1:03pm
View the Life Raft Group Policies and Disclaimer